About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Clinical Lymphoma and Myeloma
›
top-articles
Clinical Lymphoma and Myeloma
1.4
(top 50%)
impact factor
407
(top 50%)
papers
7.4K
(top 20%)
citations
42
(top 20%)
h
-index
1.7
(top 50%)
impact factor
840
all documents
7.6K
doc citations
60
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Clinical Lymphoma and Myeloma
2008
171
2
Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell Lymphoma
Clinical Lymphoma and Myeloma
2006
137
3
Treatment of Multiple Myeloma: A Comprehensive Review
Clinical Lymphoma and Myeloma
2009
135
4
Hodgkin Lymphoma: An Update on its Biology with New Insights into Classification
Clinical Lymphoma and Myeloma
2009
127
5
Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia
Clinical Lymphoma and Myeloma
2006
107
6
Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis
Clinical Lymphoma and Myeloma
2009
106
7
Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors
Clinical Lymphoma and Myeloma
2009
101
8
New Thrombopoietic Growth Factors
Clinical Lymphoma and Myeloma
2009
95
9
Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma
Clinical Lymphoma and Myeloma
2008
88
10
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
Clinical Lymphoma and Myeloma
2009
88
11
Waldenström's Macroglobulinemia: Hyperviscosity Syndrome and Cryoglobulinemia
Clinical Lymphoma and Myeloma
2009
86
12
Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab
Clinical Lymphoma and Myeloma
2006
82
13
Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma
Clinical Lymphoma and Myeloma
2006
79
14
Cardiac Involvement with Lymphoma: A Review of the Literature
Clinical Lymphoma and Myeloma
2008
78
15
Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study
Clinical Lymphoma and Myeloma
2009
70
16
T-Cell Lymphoblastic Lymphoma and T-Cell Acute Lymphoblastic Leukemia: A Separate Entity?
Clinical Lymphoma and Myeloma
2009
65
17
Therapeutic Targeting of NOTCH1 Signaling in T-Cell Acute Lymphoblastic Leukemia
Clinical Lymphoma and Myeloma
2009
64
18
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia
Clinical Lymphoma and Myeloma
2009
63
19
Value of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Follicular Lymphoma: The End of a Dilemma?
Clinical Lymphoma and Myeloma
2008
60
20
Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma
Clinical Lymphoma and Myeloma
2008
59
21
Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
Clinical Lymphoma and Myeloma
2009
56
22
Amyloidosis: Diagnosis and Management
Clinical Lymphoma and Myeloma
2005
54
23
Non-Hodgkin's Lymphoma Involving the Liver: Clinical and Therapeutic Consideration
Clinical Lymphoma and Myeloma
2006
54
24
AMD3100 Affects Autograft Lymphocyte Collection and Progression-Free Survival After Autologous Stem Cell Transplantion in Non-Hodgkin Lymphoma
Clinical Lymphoma and Myeloma
2007
54
25
Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
Clinical Lymphoma and Myeloma
2008
54
26
Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer Trials
Clinical Lymphoma and Myeloma
2005
50
27
Targeting B-Lymphocyte Stimulator/B-Cell Activating Factor and a Proliferation-Inducing Ligand in Hematologic Malignancies
Clinical Lymphoma and Myeloma
2006
50
28
Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy
Clinical Lymphoma and Myeloma
2006
50
29
IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström's Macroglobulinemia
Clinical Lymphoma and Myeloma
2009
50
30
High-Risk Childhood Acute Lymphoblastic Leukemia
Clinical Lymphoma and Myeloma
2009
50
31
Update of the M. D. Anderson Cancer Center Experience with Hyper-CVAD and Rituximab for the Treatment of Mantle Cell and Burkitt-Type Lymphomas
Clinical Lymphoma and Myeloma
2007
49
32
Incidence of Lymphoma in Patients with Rheumatoid Arthritis: A Systematic Review of the Literature
Clinical Lymphoma and Myeloma
2008
49
33
Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia
Clinical Lymphoma and Myeloma
2009
48
34
A Comparison of Inpatient Length of Stay and Costs Among Patients with Hematologic Malignancies (Excluding Hodgkin Disease) Associated with and Without Acute Renal Failure
Clinical Lymphoma and Myeloma
2008
47
35
Multiple Myeloma and Hyperammonemic Encephalopathy: Review of 27 Cases
Clinical Lymphoma and Myeloma
2008
47
36
Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study
Clinical Lymphoma and Myeloma
2009
47
37
Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma
Clinical Lymphoma and Myeloma
2006
46
38
Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma
Clinical Lymphoma and Myeloma
2006
46
39
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity
Clinical Lymphoma and Myeloma
2009
45
40
Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma
Clinical Lymphoma and Myeloma
2007
44
41
An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma
Clinical Lymphoma and Myeloma
2008
44
42
Monoclonal Gammopathy of Undetermined Significance
Clinical Lymphoma and Myeloma
2005
43
43
Pentostatin/Cyclophosphamide with or Without Rituximab: An Effective Regimen for Patients with Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Clinical Lymphoma and Myeloma
2005
43
44
Fatal Interstitial Pneumonitis Related to Rituximab-Containing Regimen
Clinical Lymphoma and Myeloma
2006
43
45
Cold Agglutinin–Mediated Autoimmune Hemolytic Anemia in Waldenström's Macroglobulinemia
Clinical Lymphoma and Myeloma
2009
43
46
Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma
Clinical Lymphoma and Myeloma
2006
42
47
Bing-Neel Syndrome Revisited
Clinical Lymphoma and Myeloma
2009
42
48
Successful Completion of Pregnancy in a Patient With Chronic Myeloid Leukemia Without Active Intervention: A Case Report and Review of the Literature
Clinical Lymphoma and Myeloma
2009
42
49
Minimal Residual Disease Quantitation in Acute Myeloid Leukemia
Clinical Lymphoma and Myeloma
2009
42
50
CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders
Clinical Lymphoma and Myeloma
2006
41
site/software ©
exaly
; All materials licenced under
CC by-SA
.